342 related articles for article (PubMed ID: 16539392)
1. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
[TBL] [Abstract][Full Text] [Related]
2. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
Seto M; Miyamoto N; Aikawa K; Aramaki Y; Kanzaki N; Iizawa Y; Baba M; Shiraishi M
Bioorg Med Chem; 2005 Jan; 13(2):363-86. PubMed ID: 15598559
[TBL] [Abstract][Full Text] [Related]
3. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
[TBL] [Abstract][Full Text] [Related]
5. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
6. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
[TBL] [Abstract][Full Text] [Related]
7. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
Ma D; Yu S; Li B; Chen L; Chen R; Yu K; Zhang L; Chen Z; Zhong D; Gong Z; Wang R; Jiang H; Pei G
ChemMedChem; 2007 Feb; 2(2):187-93. PubMed ID: 17163560
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
10. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
[TBL] [Abstract][Full Text] [Related]
11. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
Skerlj R; Bridger G; Zhou Y; Bourque E; McEachern E; Langille J; Harwig C; Veale D; Yang W; Li T; Zhu Y; Bey M; Baird I; Sartori M; Metz M; Mosi R; Nelson K; Bodart V; Wong R; Fricker S; Mac Farland R; Huskens D; Schols D
Bioorg Med Chem Lett; 2011 Dec; 21(23):6950-4. PubMed ID: 22033460
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
Wang T; Zhang Z; Wallace OB; Deshpande M; Fang H; Yang Z; Zadjura LM; Tweedie DL; Huang S; Zhao F; Ranadive S; Robinson BS; Gong YF; Ricarrdi K; Spicer TP; Deminie C; Rose R; Wang HG; Blair WS; Shi PY; Lin PF; Colonno RJ; Meanwell NA
J Med Chem; 2003 Sep; 46(20):4236-9. PubMed ID: 13678401
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
[TBL] [Abstract][Full Text] [Related]
16. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H; Maeda K; Miyakawa T; Shibayama S; Matsuo M; Takaoka Y; Ito M; Koyanagi Y; Mitsuya H
J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
[TBL] [Abstract][Full Text] [Related]
17. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
[TBL] [Abstract][Full Text] [Related]
19. Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety.
Seto M; Aramaki Y; Okawa T; Miyamoto N; Aikawa K; Kanzaki N; Niwa S; Iizawa Y; Baba M; Shiraishi M
Chem Pharm Bull (Tokyo); 2004 May; 52(5):577-90. PubMed ID: 15133211
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
